▶ Full Post Text
TL;DR: Collegium ($COLL) sells patent-protected extended-release drugs for pain and ADHD. Asset-light, 61% gross margins, ~$290M owner earnings, revenue compounding ~20% for five years. Including ~$488M of net debt, the whole enterprise trades around 5.6x owner earnings. I think the market is pricing a cash-gushing business as if it's dying next year. Trading at ~$35 vs. intrinsic value around $122 (a ~70% margin of safety).
The Business
Collegium doesn't discover drugs. They buy and commercialize patent-protected, extended-release medicines for two chronic conditions: severe pain (Belbuca, Xtampza, the Nucynta franchise) and ADHD (Jornay PM, plus the newly acquired AZSTARYS). Pain is ~80% of revenue and grows slowly; ADHD is ~20% and grows fast.
It's asset-light. They own the intellectual property and outsource manufacturing, so capex runs about 0.27% of revenue. It behaves more like a toll road on a set of patents than a lab. The moat is federal patent law: no generic Jornay until 2032, no generic AZSTARYS until 2037.
The Numbers
| Line | Amount |
|---|---|
| Operating Cash Flow | $331.0M |
| Stock-Based Compensation | -$41.3M |
| WC neutralization (add-back) | +$4.4M |
| WC reinvestment | -$0.9M |
| Smoothed CapEx (5yr avg) | -$3.5M |
| **Owner Earnings** | **$289.7M** |
At ~$35, including the net debt, the enterprise sits around 5.6x owner earnings, roughly an 18% yield to enterprise value. On the equity alone it's cheaper, but the debt is real so I anchor on the enterprise multiple.
Quality metrics:
- Gross Margin: 60.68%
- Operating Margin: 24.16%
- 5yr Revenue CAGR: 20.28%
- CapEx: 0.27% of revenue
- Net Debt: $488M
- Buybacks: $150M authorization remaining
Why It's Cheap
The stock trades around 5.6x owner earnings. Three things spooked the market:
1. Generic erosion fear in the legacy pain portfolio, which is still ~80% of revenue, plus the general opioid stigma that keeps a lot of funds away.
2. Patent cliffs. Jornay PM goes generic in 2032, AZSTARYS in 2037. Finite runway.
3. A levered, ugly balance sheet: $930M total debt, $488M net debt, deeply negative tangible book, and reported ROIC of only ~6.4%. Anyone screening on clean balance sheets or high reported returns throws this out on sight.
Why I Think The Market Is Wrong
The reported returns are depressed by acquisition amortization, not by a bad business. Look at the cash: $331M of operating cash flow against basically no maintenance capex. Against a ~$1.6B enterprise value ($1.1B market cap plus $488M net debt), that's roughly an 18% owner-earnings yield.
The part everyone fears is holding. In Q1 2026 pain revenue actually grew 4%, and they turned the Nucynta generic threat into a profit-share deal with Hikma. Meanwhile Jornay PM net revenue grew ~36%. Revenue has compounded ~20% for five years and gross margins expanded to 61%.
On the debt: they funded the $650M AZSTARYS deal with cash and a term loan, leverage sits near 2x EBITDA, and they already paid down ~$50M last year. A business throwing off $330M with near-zero capex de-levers fast. Management is buying back stock and paying down debt with the cash, which is what you want when your own stock trades at a fraction of intrinsic value.
Put a conservative 15x on $9.14 of owner earnings, subtract ~$15/share of net debt, and you get roughly $122 against a ~$35 price. I use 15x rather than a 25x "toll bridge" multiple precisely because the patents expire. Even haircutting for the cliffs, you're paying a fraction of what the cash is worth.
Disclosure: I hold a position in COLL. Hard data from filings, AI-assisted writing, personal review and position. This is not financial advice.